FDA Drug Recalls
360 recalls · Class II, newest first
Aug 19, 2025
Class II · Moderate risk
Presence of Foreign Tablet/Capsule: Two (2) bottles labeled as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, 10mg, 100ct, contained one (1) tablet of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, 5 mg.
Jul 9, 2025
Class II · Moderate risk
Sub-Potent Drug: Subpotent assay results during stability testing.
May 30, 2025
Class II · Moderate risk
Failed Tablet/Capsule specifications; a product complaint was reported for burnt or melted capsules. This was determined to be a result of oxidation by leakage of capsule contents.
May 27, 2025
Class II · Moderate risk
CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.
May 27, 2025
Class II · Moderate risk
CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.
Mar 21, 2025
Class II · Moderate risk
Presence of Foreign Substance: Product complaint received for the presence of foreign material embedded resembling a metal shaving in one tablet.
Mar 7, 2025
Class II · Moderate risk
Defective Container: blister packs not properly sealed resulting in tablets being loose in the carton.
Mar 7, 2025
Class II · Moderate risk
CGMP deviations: The presence of nitrosamine impurity above the acceptable daily intake limits.
Mar 7, 2025
Class II · Moderate risk
CGMP deviations: The presence of nitrosamine impurity above the acceptable daily intake limits.
Feb 18, 2025
Class II · Moderate risk
Lack of Assurance of Sterility: due to a quality control process deviation
Feb 6, 2025
Class II · Moderate risk
Defective Container: Some packets may not be fully sealed, potentially allowing for loss of Ethanol from the product.
Jan 31, 2025
Class II · Moderate risk
Lack of Assurance of Sterility
Oct 10, 2024
Class II · Moderate risk
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Aug 30, 2024
Class II · Moderate risk
Aug 5, 2024
Class II · Moderate risk
CGMP Deviations: sterile water not used for production
Aug 5, 2024
Class II · Moderate risk
CGMP Deviations: sterile water not used for production
Jun 26, 2024
Class II · Moderate risk
CGMP Deviations and Presence of Particulate Matter: Glass
May 28, 2024
Class II · Moderate risk
Product Mix Up. A bottle of Phenazopyridine HCl tablets USP 100 mg contained Phenobarbital tablets 16.2 mg.
Apr 30, 2024
Class II · Moderate risk
Failed Impurities/Degradation Specifications
Apr 30, 2024
Class II · Moderate risk
Failed Impurities/Degradation Specifications
Apr 24, 2024
Class II · Moderate risk
Presence of Foreign Substance; Broken metal piece found embedded in tablet.
Apr 12, 2024
Class II · Moderate risk
Mar 25, 2024
Class II · Moderate risk
Failed Dissolution Specifications
Mar 12, 2024
Class II · Moderate risk
Mar 1, 2024
Class II · Moderate risk
Failed Stability Specifications